Essex was accredited to undertake a National Key Technologies R&D project of the Ninth Five-year Plan and a project of China Touch Program successively. Its products were awarded ¡°Certificate of State Level New Products¡± and ¡°Certificate of Key New Products ¡± in Guangdong Province. It is a Hi-tech Enterprise accredited by Guangdong Science and Technology Bureau and was awarded by the State Council of
the PRC ¡° the Second Prize of State Science and Technology Progress¡±
| In 1996 |
Zhuhai Essex Bio-pharmaceutical Co.Ltd was incorporated and accredited as New High Technology Enterprise by Guangdong Province. |
| In 1997
|
Essex was entrusted with one of the hi-tech projects of the State Touch Program ¨C development and Industrialization of biopharmaceutical products using recombinant bFGF as the primary active ingredient;
|
| In 1998 |
The company¡¯s first genetically engineered new drug Beifuji in liquid form and lyophilized powder form was approved by Chinese SFDA for commercialized production, and validated as state level new drug in the same year. |
| In 1999 |
The company¡¯s second genetically engineered new drug Beifushu in eye-drop form was approved by Chinese SFDA for commercialized production, and validated as state level new drug. Essex was awarded the Third Prize of State Science and Technology Progress Awards in the same year.
|
| In 2000
|
Essex was approved against GMP Validation for the first time, and obtained the GMP Certificate issued by the state. |
| In 2001
|
EssexBio Group was successfully listed on
Hong Kong Growth Enterprise Market. |
| In 2002 |
Zhuhai Essex Medipharm Co. Ltd. was incorporated. |
| In 2003 |
Direct Representative Offices (DROs) Offices were established in major provinces in China.
|
| In 2004
|
Zhuhai Essex Medipharm Co.Ltd. was approved against GSP validation; Zhuhai Essex Bio-pharmaceutical Co.Ltd. was awarded the Second Prize of State Science and Technology Progress Awards. |
| In 2005,
|
New production lines for single dose Beifushu eye drops and chemical ophthalmic solutions were set up. Beifuxin gel for external use and Beifushu eye gel were approved by Chinese SFDA for commercialized production. |
| In 2006,
|
Beifushu has been a well-known brand Rx ophthalmic solution in China. |
| In 2007
|
Zhuhai Essex was granted the exclusive agency right for Chinese market by the Italian company ABC Farmaceutici S.P.A. for its drug substance and capsules of Ursodeoxycholic
acid. |
| In 2008 |
Zhuhai Essex was granted exclusive agency right for Chinese market by the U.S. company InSite Vision Incorporated for its patented new drug AzaSite (Azithromycin ) ophthalmic solution.
|
|
Essex was certified as National Hi-tech
Enterprise in China; Established long-term partnerships with
InSite Vision Incorporated and Sun Pharmaceutical Industries
Ltd. with the purpose of introducing their innovative ophthalmic
products to China. |
| In 2009 |
Essex was
certified as Zhuhai Key Enterprise Technology Center; Our
chemical drug tobramycin eye drop was approved by SFDA for
commercial manufacture; Co-developing tosufloxacin eye drop and
betaxolol eye drop with Jinan Bestcomm Pharmaceutical R & D
Co., Ltd.; Co-developing biological tissue engineering materials
- biological amnion with Guangdong Shiguang Ophthalmologic
Research Institute |
| In 2010 |
Beifushu was
recognized as Guangdong Province Famous Brand; The construction
of Essex¡¯s new factory was kicked off. |